Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
History
Business
Sports
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts123/v4/7b/09/c8/7b09c896-46f0-4fb3-3335-0cc0308342fb/mza_2858819860156651969.jpg/600x600bb.jpg
The IMID Forum
The Immune-Mediated Inflammatory Disease Forum
387 episodes
3 weeks ago
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi.
Show more...
Education
RSS
All content for The IMID Forum is the property of The Immune-Mediated Inflammatory Disease Forum and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi.
Show more...
Education
Episodes (20/387)
The IMID Forum
Discussing RA: UPA outcomes and the impact of GCs on targeted therapies in RA
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi.
Show more...
3 weeks ago
22 minutes 30 seconds

The IMID Forum
Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
Show more...
1 month ago
13 minutes 8 seconds

The IMID Forum
Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
Show more...
1 month ago
20 minutes 47 seconds

The IMID Forum
Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
Show more...
1 month ago
9 minutes 45 seconds

The IMID Forum
Author Interview: Professor Filip Rob, 2025
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients’.
Show more...
1 month ago
25 minutes 7 seconds

The IMID Forum
Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2
Webinar highlights! Join Professor Iain McInnes and Drs Grace Wright and Melinda Gooderham as they discuss advancing patient care through an interdisciplinary approach to IMIDs. This webinar provides information on bridging care pathways, advancing IMID treatment, and case studies of interdisciplinary care.
Show more...
1 month ago
17 minutes 2 seconds

The IMID Forum
Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis.
Show more...
2 months ago
14 minutes 37 seconds

The IMID Forum
Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, Iain will review a paper by B Fautrel, in which authors compare patient characteristics and long-term management with tocilizumab in RA patients over and under 75 years of age, and tolerance of RA treatments.
Show more...
2 months ago
5 minutes 15 seconds

The IMID Forum
ACR 2025 Review Podcast
Join Doctor Sofia Ramiro and Professors Janet Pope and Atul Deodhar, as they review and discuss key data from ACR 2025 across RA, PsA, and axSpA, focusing on implications for clinical practice.
Show more...
2 months ago
40 minutes 15 seconds

The IMID Forum
ACR Daily Highlights Day 4
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesdsy, 29th of October)
Show more...
2 months ago
1 minute 48 seconds

The IMID Forum
ACR Daily Highlights: Day 3
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday 28th of October)
Show more...
2 months ago
3 minutes 49 seconds

The IMID Forum
Pathways Modulating IMIDs: Webinar Highlights Podcast
Professors Janet Pope and John Isaacs discuss all the highlights from the 'Pathways Modulating IMIDs' webinar.
Show more...
2 months ago
24 minutes 49 seconds

The IMID Forum
ACR Daily Highlights: Day 2
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, 27th of October)
Show more...
2 months ago
4 minutes 3 seconds

The IMID Forum
ACR Daily Highlights: Day 1
Join Doctor Sofia Ramiro as she summarises her top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, 26th of October)
Show more...
2 months ago
3 minutes 49 seconds

The IMID Forum
ACR 2025 Preview Podcast
Join Professors Peter Nash, Janet Pope and Atul Deodhar as they preview what they are most looking forward to this ACR, introducing some of the top chosen abstracts and posters in RA, AxSpA and PsA so that you can better plan your time at what will be a busy and exciting congress. #ACR2025
Show more...
2 months ago
22 minutes 47 seconds

The IMID Forum
Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies
Join Professor Laura Coates and Phillip Mease as they discuss the top publications in the world of PsA. This month, the conversation covered the ‘the effectiveness and safety of upadacitinib with secukinumab and adalimumab’ and ‘the efficacy of long-term treatment with risankizumab across the updated GRAPPA domains and key related conditions of PsA’.
Show more...
3 months ago
18 minutes 31 seconds

The IMID Forum
Author Interview: Doctor David Kellner, September 2025
Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor David Kellner, an IGNITE-MSCR Fellow of the Division of Rheumatology, from UCLA Medical Centre, LA, USA, as they discuss his recent review ‘Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis’.
Show more...
3 months ago
22 minutes 44 seconds

The IMID Forum
Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.
Show more...
3 months ago
8 minutes 44 seconds

The IMID Forum
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA
Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
Show more...
3 months ago
20 minutes 52 seconds

The IMID Forum
Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
Join Professor Iain McInnes as he discusses the top publications in the world of RA. This month’s discussion covered the ‘Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis’. Read the full paper summary online at www.imidforum.com.
Show more...
4 months ago
7 minutes 41 seconds

The IMID Forum
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he and Doctor Reike Alten will be reviewing two papers. The first paper by Kameda et al. assessed long-term safety and efficacy of UPA over 5 years in Japanese patients with moderate-to- severe active RA and an inadequate response to stable doses of csDMARDs-IR. The second paper by Salvato et al. assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAK inhibitors compared to other mechanisms of action therapies in a cohort of RA patients with inadequate response to TNFi.